Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an update.
Shanghai Pharmaceuticals Holding Co., Ltd. announced proposed amendments to its Articles of Association and the abolishment of its Supervisory Board, replacing it with an audit committee. These changes align with recent revisions in Chinese corporate and securities laws, aiming to streamline governance and enhance operational efficiency. The amendments are expected to impact the company’s governance structure, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, catering to both domestic and international markets.
Average Trading Volume: 3,451,346
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.17B
See more data about 2607 stock on TipRanks’ Stock Analysis page.